5-HT3 receptor antagonists: Differences and similarities

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1364-1370

  Roila, F ^a   Ballatori, E ^c   Tonato, M ^a   Del Favero, A ^b  

^a Policlinico Hospital   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c NONE

Author keywords

Anti emetics; Dolasetron; Granisetron; Ondansetron; Tropisetron

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON; ANTIEMETIC AGENT; SEROTONIN ANTAGONIST;

ANIMAL MODEL; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; REVIEW; VOMITING; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; PATIENT SATISFACTION;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; CONTROLLED CLINICAL TRIALS; DOUBLE-BLIND METHOD; HUMANS; NAUSEA; PATIENT SATISFACTION; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0030805445     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00003-8     Document Type: Review

References (33)

1. 3 receptor antagonists the same? Eur J Cancer (Suppl 1) 1992, 28A, 2-6.
2. 2) chemotherapy. Support Care Cancer 1995, 3, 338.
3. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992, 10, 1969-1975.
4. Bonneterre J, Hecquet B, on behalf of the French Northern Oncology Group. Granisetron iv compared with ondansetron iv plus tablets in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy regimen: a randomized cross-over study. Presented at a Satellite to the 7th European Conference of Clinical Oncology and Cancer Nursing, Jerusalem, Israel. 1993, Adelphi Communication, Macclesfield, U.K. 22-24.
5. Campora E, Simoni C, Rosso R. Tropisetron versus ondansetron nella prevenzione e controllo dell'emesi in pazienti sottoposte a chemioterapia con FAC/FEC per carcinoma mammario metastatico o operate. Minerva Medica 1994, 85, 25-31.
6. 3 receptor antagonists and anti-emetic mechanisms of action. Anti-Cancer Drugs 1992, 3, 79-85.
7. 4 receptors of the release of 5-hydroxytryptamine from guinea pig small intestine. Naunyn Schniedebergs Arch Pharmacol 1993, 347, 137-140.
8. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994, 74, 1945-1952.
9. Italian Group for Antiemetic Research Ondansetron + dexamethasone versus metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced. emesis. Lancet 1992, 340, 96-99.
10. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995, 6, 805-810.
11. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer 1993, 29A, 1669-1672.
12. Jantunen IT, Kataja W, Johansson RT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncol 1992, 31, 573-575.
13. Lofters WS, Zee B for the Symptom Control Committee of the National Cancer Institute of Canada Clinical Trials Group and Nordic Merrel Dow Research Canada. Dolasetron vs ondansetron with and without dexamethasone in the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Support Care Cancer 1995, 3, 338.
14. Mantovani G, Macciò A, Curreli L, et al. Comparison of grani-setron, ondansetron and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996, 77, 941-948.
15. 3 receptor antagonists. Anti-Cancer Drugs 1991, 2, 513-518.
16. Martoni A, Angelelli B, Guaraldi E, et al. Granisetron versus ondansetron in the prevention of cisplatin-induced emesis. An open randomised cross-over study. Proc ASCO 1994, 13, 431.
17. Martoni A, Angelelli B, Guaraldi E, et al. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer 1996, 32A, 82-85.
18. Marty M, d'Allens H. et le Groupe Multicentrique Francaiş. Etude randomisée en double-insu comparant l'efficacité de l'ondansetron selon deux modes d'administration: injection unique et perfusion continue. Cahiers Cancer 1992, 2, 541-546.
19. Marty M, Kleisbauer J-P, Fournel P, et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 1995, 6, 15-21.
20. 3-receptor antagonists in chemotherapy induced emesis. Support Care Cancer 1995, 3, 340.
21. 3 receptors. Ann Oncol (Suppl 8) 1994, 5, 204.
22. Mercier A, Kerbrat P, Bleuse JP, the French Granisetron Study Group. Granisetron per os day 1 followed by metoclopramide po (d2-3) compared with ondansetron iv d1 and ondansetron po d2-3 in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy. Abstract of the Sixth International Congress on Anti-Cancer Treatment, 1996 Paris 6-9 February pp. 90.
23. Navari R, Hesketh P, Grote T, et al. A double-blind, randomized, comparative iv study of single dose dolasetron vs ondansetron in preventing cisplatin-related emesis. Proc ASCO 1995, 14, 522.
24. Navari R, Hesketh P, Hall S, et al. on behalf of the Granisetron Study Group. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995, 13, 1242-1248.
25. Newberry NR, Watkins CJ, Sprosen TS, et al. BRL 40470 potently antagonizes neuronal responses by 5-HT3 receptors. Neuropharmacology 1993, 32, 729-735.
26. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994, 30A, 1083-1088.
27. Perez EA, Lembersky B, Kaywin P, et al. Intravenous granisetron vs ondansetron in the prevention of cyclophosphamide-doxorubicin-induced emesis in breast cancer patients: a double-blind crossover study. Proc ASCO 1996, 15, 543.
28. Pion JM, Fournier C, Darloy F, et al. Oral granisetron vs oral ondansetron, a comparative double-blind cross-over multicenter study of preventive anti-emetic in moderately emetogenic chemotherapy, by the French Northern Oncology Group (FNOG). Proc ASCO 1996, 15, 530.
29. Ruff P, Paska W, Goedhals L, et al. on behalf of the Ondansetron and Granisetron Emesis Study Group. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel group study. Oncology 1994, 51, 113-118.
30. Seynaeve C, Schuller J, Buser K, et al. Comparison of the antimetic efficacy of different doses of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cis-platin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992, 66, 192-197.
31. Spina M, Valentini M, Fedele P, et al. Randomized comparison of granisetron vs ondansetron in patients with HIV-related non Hodgkin's lymphoma receiving moderately emetogenic chemotherapy. Proc ASCO 1995, 14, 532.
32. Stewart A, McQuade B, Cronje JDE, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Oncology 1995, 52, 202-210.
33. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995, 332, 1-5.